Mucosal vaccination in a murine gnotobiotic model of Giardia lamblia infection.
Infect Immun
; 92(6): e0006524, 2024 Jun 11.
Article
em En
| MEDLINE
| ID: mdl-38722167
ABSTRACT
Giardia lamblia is an important protozoan cause of diarrheal disease worldwide, delayed development and cognitive impairment in children in low- and middle-income countries, and protracted post-infectious syndromes in developed regions. G. lamblia resides in the lumen and at the epithelial surface of the proximal small intestine but is not mucosa invasive. The protozoan parasite is genetically diverse with significant genome differences across strains and assemblages. Animal models, particularly murine models, have been instrumental in defining mechanisms of host defense against G. lamblia, but mice cannot be readily infected with most human pathogenic strains. Antibiotic pretreatment can increase susceptibility, suggesting that the normal microbiota plays a role in controlling G. lamblia infection in mice, but the broader implications on susceptibility to diverse strains are not known. Here, we have used gnotobiotic mice to demonstrate that robust intestinal infection can be achieved for a broad set of human-pathogenic strains of the genetic assemblages A and B. Furthermore, gnotobiotic mice were able to eradicate infection with a similar kinetics to conventional mice after trophozoite challenge. Germ-free mice could also be effectively immunized by the mucosal route with a protective antigen, α1-giardin, in a manner dependent on CD4 T cells. These results indicate that the gnotobiotic mouse model is powerful for investigating acquired host defenses in giardiasis, as the mice are broadly susceptible to diverse G. lamblia strains yet display no apparent defects in mucosal immunity needed for controlling and eradicating this lumen-dwelling pathogen.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Giardíase
/
Giardia lamblia
/
Modelos Animais de Doenças
/
Vida Livre de Germes
Limite:
Animals
/
Female
/
Humans
Idioma:
En
Revista:
Infect Immun
Ano de publicação:
2024
Tipo de documento:
Article
País de afiliação:
Estados Unidos